Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Döring, Michaela ^a   Müller, Carsten ^b   Johann, Pascal David ^c   Erbacher, Annika ^a   Kimmig, Astrid ^a   Schwarze, Carl Philipp ^a   Lang, Peter ^a   Handgretinger, Rupert ^a   Müller, Ingo ^d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antifungal prophylaxis; Pediatric patients; Posaconazole; Posaconazole trough levels; Stem cell transplantation

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; CASPOFUNGIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; OMEPRAZOLE; POSACONAZOLE; RANITIDINE; THIOTEPA; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; COFFEE; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAT INTAKE; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; HUMAN CELL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OUTPATIENT CARE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SIDE EFFECT; SUSPENSION; TREATMENT DURATION;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MALE; MYCOSES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TRIAZOLES;

EID: 84870498586     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-263     Document Type: Article

References (27)

1. Fisher BT, Zaoutis TE. Treatment of invasive candidiasis in immunocompromised pediatric patients. Paediatr Drugs 2008, 10:281-298. 10.2165/00148581-200810050-00003, 18754696.
2. Groll AH, Ritter J, Muller FM. Prevention of fungal infections in children and adolescents with cancer. Klin Padiatr 2001, 213:A50-A68. 10.1055/s-2001-17502, 11577364.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001, 32:358-366. 10.1086/318483, 11170942.
4. Döring M, Hartmann U, Erbacher A, Lang P, Handgretinger R, Müller I. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. BMC Infect Dis 2012, 12:151. 10.1186/1471-2334-12-151, 3449185, 22747637.
5. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2-12. 10.1086/508774, 17143808.
6. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006, 42:1398-1403. 10.1086/503425, 16619151.
7. Van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-e65. Epub 2006 Feb 21. Erratum in: Clin Infect Dis 2006, 43:1376, 10.1086/500212, 16511748.
8. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, Ullmann AJ. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006, 42:1726-1734. 10.1086/504328, 16705579.
9. Schering Corporation Prescribing information for Noxafil (posaconazole) oral suspension 2008, Kenilworth, NJ: Schering Corporation, Schering Corporation.
10. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004, 48:3543-3551. 10.1128/AAC.48.9.3543-3551.2004, 514780, 15328123.
11. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004, 21:645-653. 10.1016/j.ejps.2004.01.005, 15066665.
12. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359. 10.1056/NEJMoa061094, 17251531.
13. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais De Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335-347. 10.1056/NEJMoa061098, 17251530.
14. Winston DJ, Bartoni K, Territo MC, Schiller GJ. Efficacy, Safety, and Breakthrough Infections Associated with Standard Long-Term Posaconazole Antifungal Prophylaxis in Allogeneic Stem-Cell Transplant Recipients. Biol Blood Marrow Transplant 2011, 17:507-515. Epub 2010 May 9, 10.1016/j.bbmt.2010.04.017, 20460163.
15. de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821. 10.1086/588660, 2671227, 18462102.
16. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health Common terminology criteria for adverse events v3.0 (CTCAE) 2006, Bethesda, MD: Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health.
17. Müller C, Arndt M, Queckenberg C, Cornely OA, Theisohn M. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses 2006, 49:17-22. 10.1111/j.1439-0507.2006.01297.x, 16961577.
18. Grigull L, Kuehlke O, Beilken A, Sander A, Linderkamp C, Schmid H, Seidemann K, Sykora KW, Schuster FR, Welte K. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy. Pediatr Transplant 2007, 11:261-266. 10.1111/j.1399-3046.2006.00643.x, 17430480.
19. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, Gachot B, Heinz WJ, Lass-Flörl C, Ribaud P, Thiebaut A, Cordonnier C. Third European Conference on Infections in Leukemia: European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011, 46:709-718. 10.1038/bmt.2010.175, 20661235.
20. Lehrnbecher T, Attarbaschi A, Duerken M, Garbino J, Gruhn B, Kontny U, Lüer S, Phillips R, Scholz J, Wagner HJ, Wiesel T, Groll AH. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010, 29:1043-1045. 10.1007/s10096-010-0957-4, 20495990.
21. Cesaro S, Milano GM, Aversa F. Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis 2011, 30:595-596. Epub 2010 Dec 1, 10.1007/s10096-010-1123-8, 21120565.
22. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007, 27:1627-1636. 10.1592/phco.27.12.1627, 18041883.
23. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006, 50:658-666. 10.1128/AAC.50.2.658-666.2006, 1366875, 16436724.
24. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012, 56:2806-2813. 10.1128/AAC.05900-11, 22391534.
25. Krishna G, Sansone-Parson A, Martino M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007, 51:812-818. 10.1128/AAC.00454-06, 1803109, 17210771.
26. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009, 53:958-966. 10.1128/AAC.01034-08, 2650585, 19075045.
27. Amigues I, Cohen N, Chung D, Seo SK, Plescia C, Jakubowski A, Barker J, Papanicolaou GA. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:46-52. 10.1016/j.bbmt.2009.08.015, 3094157, 20053331.